

Special Issue

Microbiome in Inflammatory Bowel Disease (IBD)

Message from the Guest Editors

It is well known that the incidence of inflammatory bowel disease (IBD) is increasing significantly in developing countries, while in others, it has now reached a plateau. The purpose of this Special Issue is to define the role of the gut microbiome in the pathogenesis of IBD so that a more personalized therapeutic approach through exogenous modification of the gut microbiome could be possible shortly. We cordially invite authors to submit original research and review articles focusing on this important and rapidly expanding field of biomedicine.

Potential topics include but are not limited to:

- Gut microbiome, dysbiosis, and pathogenesis of IBD;
- Probiotics and gut microbiome;
- Fecal transplantation in the treatment of IBD;
- Potential link between gut microbiome, COVID-19, and outcome of IBD;
- Extraintestinal manifestations of IBD: Is there any link with the gut microbiome?
- Intestinal yersiniosis, probiotics, and gut microbiome;
- Autophagy, gut microbiome, and IBD;
- Inflammasomes, IBD, and gut microbiome;
- Nutritional aspects and gut microbiome in IBD: the role of the Mediterranean diet;
- Vitamin D and intestinal homeostasis: the role of gut microbiome.

Guest Editors

Dr. John K. Triantafyllidis

Director IBD Unit, Metropolitan General Hospital, 15562 Holargos, Greece

Dr. Ferenc Sipos

Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary

Deadline for manuscript submissions

closed (31 October 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/135223

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).